Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Calls Glaxo Ad For Prostate Drug ‘Misleading’

By Pharmaceutical Processing | March 2, 2009

By MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — A marketing campaign for a GlaxoSmithKline prostate drug has drawn complaints from federal regulators, who said the space-themed advertisement is misleading. The British drugmaker’s Avodart capsules treat symptoms of enlarged prostate, including frequent urination. In the company’s advertisement, a man working on a model of the solar system is forced to stop painting to make frequent trips to the bathroom. A colleague then recommends he take Avodart, adding that “other medicines, they don’t treat the cause, because they don’t shrink the prostate.” But FDA regulators say that claim is false. In a letter to the company’s U.S. management, the FDA said Merck & Co. Inc.’s Proscar also reduces the size of the prostate, and has a similar indication. “Nothing in the labeling for Avodart suggests any specific advantage,” states the FDA letter, which was posted online Friday. Regulators also take issue with the visuals used to promote the drug. At one point the ad shows a man holding a model of a planet which is quickly replaced with a much smaller planet, to demonstrate Avodart’s prostate-shrinking power. The FDA says the visual exaggerates the drug’s effect, which has been shown to reduce the prostates size about 25 percent after two years. “The planet shrinking in size represents a reduction in prostate volume that is much greater than the reduction actually achieved with Avodart,” states the agency. The FDA’s letter, dated last week, calls on the company to respond to the agency’s concerns by March 4. Company spokeswoman Sarah Alspach said in a statement Friday the ad has not aired since last fall, and that the company “is committed to responsible marketing.” The company’s U.S. operations are based in Research Triangle Park, N.C. The FDA regularly issues warning letters to companies that do not follow regulations for manufacturing and marketing. The letters are not legally binding, but the agency can take companies to court if they are ignored. Avodart won approval in the U.S. in 2001 has become a strong revenue driver for Glaxo, the world’s second-largest drugmaker. The company is also testing the drug as a preventive treatment against prostate cancer. Enlarged prostate affects half of men over 50 and 90 percent of men over 80.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE